KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Shares Outstanding (2016 - 2025)

Rigel Pharmaceuticals has reported Shares Outstanding over the past 16 years, most recently at $18.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $18.3 million for Q4 2025, up 3.39% from a year ago — trailing twelve months through Dec 2025 was $18.3 million (up 3.39% YoY), and the annual figure for FY2025 was $18.3 million, up 3.39%.
  • Shares Outstanding for Q4 2025 was $18.3 million at Rigel Pharmaceuticals, up from $18.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for RIGL hit a ceiling of $172.8 million in Q2 2022 and a floor of $17.2 million in Q4 2021.
  • Median Shares Outstanding over the past 5 years was $17.8 million (2024), compared with a mean of $63.8 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 89.91% in 2023 and later rose 3.39% in 2025.
  • Rigel Pharmaceuticals' Shares Outstanding stood at $17.2 million in 2021, then rose by 1.05% to $17.3 million in 2022, then increased by 0.82% to $17.5 million in 2023, then rose by 1.3% to $17.7 million in 2024, then grew by 3.39% to $18.3 million in 2025.
  • The last three reported values for Shares Outstanding were $18.3 million (Q4 2025), $18.1 million (Q3 2025), and $17.9 million (Q2 2025) per Business Quant data.